EU approves Cabozantinib for advanced kidney cancer

EU approves Cabozantinib for advanced kidney cancer

The European Medicines Agency (EMA) has approved Cabozantinib as a second-line treatment option for patients with advanced renal cell carcinoma (RCC) who have previously been treated with vascular endothelial growth factor (VEGF)-targeted therapy.  Read more.

2016-09-23T16:01:01+00:00September 23rd, 2016|Drug treatments, Treatment Options|
This website uses cookies and third party services to provide a better service. Please confirm you are okay with this. I agree